FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | Sample | Privacy

Heparin likely weaker, but safer

Beginning this week, a manufacturing change to the anti-clotting drug heparin will likely decrease its potency, according to an FDA alert.

As a hedge against contamination, following a Baxter recall traced to active ingredient contamination at a plant in China, the United States Pharmacopeia (USP) has adopted new manufacturing controls, which include a modification of the reference standard for the drug's unit dose. The changes match those of the World Health Organization's International Standard (IS) unit dose definition in use in Europe. The revised reference standard and unit definition for heparin is about 10 percent less potent than the former version.

The FDA says that manufacturers for the U.S. market have begun to make heparin using the new USP standard, which became effective October 1, 2009, for production. At FDA request, however, manufacturers have held shipments until at least October 8 to give health care providers and facilities time to make adjustments.

- here's the FDA alert

Related Articles:
Baxter: Tests show suspect heparin was pure
FDA investigating deaths of heparin patients
FDA seizes tainted Celsus heparin
FDA finds 'final link' in heparin case


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Manufacturing Email Newsletter:
Comments (1) | Post a comment
More stories about China   contamination   FDA guidance   Heparin   United States Pharmacopeia  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.